Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Vepdegestrant PK in Healthy Adults
NCT05538312Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity, Maximum Observed Plasma Concentration and 1 more. Started Feb 2023; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05538312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538312.